PHARMACOLOGICAL AND CLINICAL MANAGEMENT OF SCHIZOPHRENIA: MECHANISMS, THERAPEUTIC MONITORING, AND PHARMACIST CONTRIBUTIONS
Schizophrenia is a long-term and debilitating mental illness that has positive, negative, and cognitive symptoms that significantly affect social, occupational, and functional health. Its pathophysiology is multifactorial and deals with the dysregulation of dopaminergic systems, glutamatergic anomalies, and neurodevelopmental abnormalities which in combination affect the development and course of the disease. The pillar of the treatment is the use of antipsychotics pharmacotherapy, and both oral and long-acting injectable versions contribute significantly to controlling the symptoms and relapse prevention in the treatment. Non-adherence to medication, metabolic imbalances, extrapyramidal symptoms, and polypharmacy are often complex in the course of treatment, however. A good management thus involves consistent monitoring of therapeutic progress, selection of drugs to be used, and prompt detection of side effects. Pharmacists can play an important role in the treatment of schizophrenia by overseeing medication therapy, counselling patients, monitoring their metabolic and safety status, supporting patient adherence, and working in a multidisciplinary setting. Moreover, patient and caregiver education enhances the involvement in the treatment and long-term care outcomes. Interventions based on a multifaceted, individualized approach to encompassing both pharmacological treatment and monitoring and pharmacist-led interventions is imperative in enhancing clinical outcomes and quality of life in schizophrenia.